IOL Chemicals and Pharmaceuticals Ltd
NSE:IOLCP
IOL Chemicals and Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
Revenue Growth: Revenue from operations reached INR 580 crores in Q3 FY '26, up 10.9% year-on-year.
Margin Expansion: EBITDA margin improved to 10.7% in Q3, driven mainly by higher capacity utilization.
Strong Chemical Performance: Chemicals EBIT nearly doubled year-on-year on full capacity utilization of the ethyl acetate plant.
Ibuprofen Running Strong: Ibuprofen API plant operated at 90–95% utilization with no oversupply issues.
Power & Fuel Costs: Elevated fuel costs persisted into Q3 due to high rice husk prices, impacting margin targets.
Product Diversification: Non-ibuprofen APIs gained market share, especially in regulated markets, supporting the company’s diversification strategy.
Guidance Maintained: Management reaffirmed 10–15% revenue growth and 15–20% bottom-line growth for FY '27, targeting INR 2,700 crores in revenue.
Dividend Declared: Board declared an interim dividend of 50% per equity share for FY '25-26.
